Particle.news

Propranolol Extended‑Release Capsules Recalled Nationwide Over Possible Metal Contamination

Breckenridge says metal fragments tied to a shared intermediate material used by its contract manufacturer could cause internal lacerations and led to a voluntary nationwide withdrawal.

Overview

  • On Monday, Nov. 16, Breckenridge Pharmaceutical issued a voluntary nationwide recall for one lot of 60 mg propranolol hydrochloride extended‑release capsules (NDC 51991‑817‑01, lot PK25110035, exp. May 2029) that was distributed Oct. 26–Nov. 4.
  • The company warned the capsules may contain metal fragments that could lacerate the mouth, esophagus, stomach or intestines and said no adverse health events had been reported as of the announcement.
  • Breckenridge identified Adare Pharma Solutions as the contract manufacturer and said a shared intermediate material is suspected as the source of the metal contamination found in a separate lot that was not released to market.
  • Wholesalers, pharmacies and retailers were told to check and quarantine inventories of the affected lot while consumers were advised to stop taking the pills, contact their health care provider, return unused product to the dispensing pharmacy, and report problems to FDA MedWatch.
  • The recall follows several blood‑pressure drug quality problems this fall and highlights risks tied to outsourced manufacturing and shared supply‑chain materials for generic medicines.